Pemphigus Vulgaris Treatment Market Future Growth Analysis and Forecast 2018-2026

Pemphigus Vulgaris is an autoimmune disorder in which painful blisters are formed on the mucus membrane and skin. The disorder is rare and affects mouth, nose, throat, lungs, eyes, and sometimes genitals. The disorder is caused when the body produces antibodies against self-cells, although the exact cause and mechanism is unknown. Formation of Immunoglobulin G (IgG) antibodies against self desmosomal adhesion proteins, present on epidermal keratinocytes, results in blister formation. Its diagnosis involves biopsy (tissue sampling), blood tests for pemphigus specific antibodies, and endoscopy. The treatment involves administration of immunosuppressant drugs and corticosteroids.

Get PDF Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2530

New drug approvals is expected to drive the global pemphigus vulgaris treatment market growth over the forecast period. For instance, in June 2018, the U.S. Food and Drug Administration (FDA) approved the use of Rituximab for the treatment of pemphigus vulgaris. Rituximab is a humanized anti-cd20 monoclonal antibody and acts to reduce the number of skin lesions. The drug acts by targeting cd20 antigen, expressed on cells of B cell lineage and kills B cells. Rituximab acts by inhibiting cell proliferation and inducing cell apoptosis. Rituximab has minimal immunogenicity and can be reused.

Moreover, active research and development by key manufacturers is expected to have positive impact on the global pemphigus vulgaris treatment market growth. For instance, F. Hoffmann-La Roche AG, in collaboration with Genentech, Inc., is conducting a Phase-3 clinical trial (estimated study completion by November 2019) to check the efficacy and safety of drug rituximab as compared to Mycophenolate Mofetil. Rituximab is a U.S.FDA approved drug for the treatment of pemphigus vulgaris and Mycophenolate Mofetil is a drug which, according to National Centre for Biotechnology Information (NCBI), is found to be an effective adjuvant that increases the immunosuppressive effect.

Moreover, Principia Biopharma, a U.S.-based late stage biopharmaceutical company, is conducting Phase-3 clinical trial (estimated study completion by December 2019) for PRN1008 drug, which is a covalent inhibitor of BTK (Bruton’s tyrosine kinase), in pemphigus vulgaris patients. Treatment with PRN1008 was found to inhibit the B cell activation and antibody mediated immune cell activation. These factors are expected to support the global pemphigus vulgaris treatment market growth over the forecast period.

Argenx SE, a Netherlands-based biopharmaceutical company, is conducting Phase-2 clinical trial (estimated study completion by August 2019) to check the efficacy of ARGX-113 in treatment of pemphigus vulgaris. ARGX-113 is an antibody Fc fragment (crystallizable fragment), which acts against neonatal Fc Receptor, involved in IgG half-life prolonging pathway and ultimately leading to persistence of autoantibodies, thus mediating the removal of autoantibodies from the system. Therefore, increasing number of clinical trials to develop new therapies for pemphigus vulgaris is expected to fuel the Europe pemphigus vulgaris treatment market growth over the forecast period.

According to the U.S. National Library of Medicine, in rare cases, use of nonsteroidal anti-inflammatory drugs is a cause of pemphigus vulgaris. This restricts the use of anti-inflammatory agents in the pemphigus, which is characterized by blisters containing inflammatory mediators. Moreover, Rituximab, the only U.S. FDA approved drug used for treatment of pemphigus vulgaris, has side effects such as joint or muscle pain, anemia, kidney problems, muscle spasms, and in rare cases allergic reactions. Such side effects are expected to restrain the global pemphigus vulgaris treatment market growth over the forecast period.

Click To Continue Reading On Pemphigus Vulgaris Treatment Market

Some of the key players operating in the global pemphigus vulgaris treatment market include, Principia Biopharma, Argenx SE, Alexion Inc., Genentech, Inc., Novartis International AG, GlaxoSmithKline plc. Vifor Pharma Management Ltd., and F. Hoffmann-La Roche AG

Saliva Collection Devices Market to Perceive Substantial Growth and Forecast 2018-2026

Saliva is the most favored sample of choice in diagnosis due to ease of collection. Salivary biomolecules have provided an aperture in surveying a person’s health and well-being. Saliva contains a myriad of salivary proteins, which could serve as biological markers for diagnosing and tracking the progression of various health conditions, as well as monitoring the effectiveness of medication. Saliva collection devices allow a person to collect resting (unstimulated) saliva or stimulated saliva either via mechanical stimulation or acid stimulation.

Get a PDF Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2523

Rising research activities for saliva collection devices is expected to boost growth of the saliva collection devices in the market. For instance, in July 2017, EquiSal Tapeworm saliva test was launched in the U.S. for detecting tapeworms from saliva of horses. EquiSal saliva collection kits are used for saliva collection, which comprises swabs to be kept in oral cavity of horses.

Furthermore, new marketing strategies by key players are expected to drive growth of the saliva collection devices market over the forecast period. For instance, in October 2018, Mayo Clinic and Helix’s lab launched a solution called, Mayo Clinic GeneGuide. It allows shipment of saliva collection kits to the individual within two days and furthermore, DNA is sequenced for identifying diseases.

Furthermore, in January 2015, DNA Genotek Inc., received USFDA approval for Oragene Dx intended for use in the non?invasive collection of saliva samples. DNA from the saliva sample is then isolated, stabilized, and legally marketed for DNA carrier screening genotyping tests.

North America held the major share in the global saliva collection devices market during the forecast period, owing to increasing number of new and innovative product launches in the U.S. For instance, in June 2016, DNA Genotek launched saliva sample collection device ORAcollectDx, an alternative to buccal swabs. The device, ORAcollectDx, is part of saliva-based DNA collection and stabilization devices.

Asia Pacific is expected to witness the fastest growth in the global saliva collection devices market the forecast period, due to increasing awareness for safe and easy diagnosis of various diseases through number of symposiums and conferences organized in the region. For instance, in October 2016, Saliva Technology Application Research Symposium was held by Queensland University of Technology, in Australia.

Click To Continue Reading On Saliva Collection Devices Market

Key players operating in the saliva collection devices market include Quest Diagnostics, Neogen Corporation, AboGen, Inc., OraSure Technologies, Inc., Oasis Diagnostics Corporation, Alere, Porex Corporation., and Salimetrics, LLC.

Cell Processing Market to Expand Steadily in the Coming Years till 2018-2026

Cell processing includes a series of activities from collection of cells from donor, extraction of cell till the storage, and distribution of cells to receiver for cell therapy. Cell therapy is defined as the administration of living whole cells in a patient for the treatment of a disease. The origin of the cells can be from the same individual (autologous source) or from another individual (allogeneic source). Different types of cells can be used for cell therapy such as hematopoietic stem cell, embryonic stem cell, skeletal muscle cells, mesenchymal cells, and neural cells.

Get a PDF Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2518

The global cell processing market size is expected to increase, owing to rising demand for cell therapy. Cell therapy is the only curative treatment for many diseases such as cancer, autoimmune disease, and neural disease. According to the Worldwide Network for Blood and Marrow Transplantation (WBMT), in 2012, around one million stem cell transplantations were performed, worldwide.

Continuous research and development for new innovative techniques for cell isolation, concentration, and preservation is another major factor driving the cell processing market size. According to University of California, Los Angeles (UCLA) 2016 research report, researchers have developed a new magnetic ratcheting system to separate and organize cells suspended in fluid samples by their subtle biochemical differences.

The major restraining factors affecting the cell processing market revenue includes safety issues for patients, commercialization of cells. It also includes safety issues for preservation and distribution of cells or customized cell therapies for patients. For instance, in 2014, a U.S.-based company Athersys Inc. along with Pfizer conducted a clinical trial on stem cell product Multistem infusion in patients with ulcerative colitis. The trial failed to meet efficacy end points from the FDA in interim analysis.

North America holds dominant position in the cell processing market, owing to new technological developments in the field. For instance, Cesca Therapeutics, a U.S.-based company, launched a new device for cell processing CAR-TXpress in 2017. The device integrates multicomponent automation steps, including T-cell isolation, purification, culture expansion and washing, single cassette-based automated -196°C cryopreservation, and retrieval of cells.

Asia Pacific cell processing market revenue is expected to witness significant growth during the forecast period due to increasing number of cell banks in economies such as China, India, Singapore, and Malaysia. A Singapore-based company Cordlife has the largest cord blood bank in Singapore and is the first bank in Southeast Asia to achieve dual accreditation from the American Association of Blood Banks (AABB) & Foundation for the Accreditation of Cellular Therapy (FACT).

Click To Continue Reading On Cell Processing Market

Major players operating in the global cell processing market include Beckman Coulter, Inc. (subsidiary of Danaher Corporation), Becton, Dickinson and Company, GE Healthcare, Lonza Group, Merck KGaA, Miltenyi Biotec, Sartorius AG, Stemcell Technologies, Terumo Bct, Inc. (subsidiary of Terumo Corporation), Thermo Fisher Scientific Inc., Cesca Therapeutics, Biosafe, Cryo-Cell, and Americord.

Swab Market to See Incredible Growth and Forecast 2018-2026

Swabs are made of absorbent material, which imparts medicinal properties to it. Swab is part of surgery and medicine and it is used in surgical procedures, injuries, at pre injection site and in diagnostic kits to obtain sample. The major role of swab is wound cleansing and disinfection. The antiseptics used in swab are iodine, cetrimide and disinfectant such as alcohol.

Increasing prevalence of accidents and falls cause’s injuries, which is expected to increase surgical procedures, in turn driving swab market growth. According to World Health Organization (WHO) factsheet in 2018, annually there are around 37.3 million falls, which require medical attention, whereas an estimated 646,000 individuals die annually from falls globally. Moreover, increasing prevalence of cardiovascular disease is expected to propel treatment via surgery, which is expected to boost the market growth.

Get a PDF Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2513

According to the, World Health Organization (WHO) published in 2009, around 3.8 million men and 4.4 million women die annually from coronary heart disease worldwide. Moreover, according to the same source, the mortality for age between 15 to 59 years, was around 1,332, 000 and for above 60 years of age, it was around 5,825, 000.

Key players in the market are focused on research and development in order to develop novel products to address the critical unmet needs of patients. For instance, in November 2018, Meridian Bioscience Inc. received approval from Food and Drug Administration (FDA) for Alethia CMV Assay Test System, which is used in detection of cytomegalovirus in newborn babies under age of 21 days by using saliva swab.

Moreover, increase in geriatric population is expected to rise incidences of chronic diseases, which in turn is expected to boost the market growth. For instance, according to the Centers for Disease Control and Prevention (CDC), in May 2016, around 19% of the population in the U.S. is projected to fall in the geriatric category by 2030. Moreover, in the U.S., around 40 million individuals age above 65 years are affected by cardio vascular diseases.

The government initiatives for free diagnostic test is expected to boost the market growth. For instance, in union budget 2014 -15, the Government of India announced free drug service and free diagnostic test initiative under the National Health Mission (NHM). In July 2015, the Ministry of Health and Family Welfare (MoHFW) formulated guidelines and shared it to states and union territories.

Increasing geriatric population susceptible to cardiovascular disease in this region is expected to bolster the market growth over the forecast period. According to the American Heart Association, December 2015, an estimated 85.6 million Americans suffers from some form of cardiovascular disease and nearly 50% of African and America adults are diagnosed with cardiovascular disease in which women comprised around 48% and men around 46%

Moreover, key players in the market are focused on receiving the U.S. Food and Drug Administration (FDA) approval for novel products in diagnostic tools. For instance, in April 2018, Parsagen Diagnostic Inc., received the U.S. Food and Drug Administration (FDA) approval for PartoSure test, which consist of sterile flocked swab, lateral flow test strip, and vial with extraction solvent.

Click To Continue Reading On Swab Market

Major players operating in the global swab market include Puritan Medical Products, Copan Diagnostics, Inc., Sarstedt AG & Co. KG, FI Medical MWE, Cleancross Co.,LTD., AdvaCare Systems, GPC Medical Ltd., Elmex Controls Pvt Ltd., and Citotest Labware Manufacturing Co., Ltd.

Macular Edema Treatment Market To Increase at Steady Growth and Forecast 2018-2026

Macular edema is the condition characterized by abnormal leakage and accumulation of fluid that forms blister in the layer of macula. The macula is an oval-shaped pigmented area near the center of retina. This blister causes the macula to swell and thicken that causes distortion of vision. Although macular edema has numerous causes, the most common cause is diabetes. Other causes include, age-related macular degeneration, replacement of lenses in treatment of cataract, chronic uveitis and intermediate uveitis, blockage of vein in the retina, and congenital diseases including retinitis pigmentosa and retinoschisis.

Get a PDF Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2494

Increasing number of pipeline studies is expected to drive the macular edema treatment market growth. For instance, in April 2018, University of California, Davis, in collaboration with IRIDEX Corporation, initiated phase 3 clinical trial for Micropulse Laser Treatment to evaluate micropulse for suppression of diabetic macular edema (pulse). The primary aim of the study is to determine whether the micropulse laser treatment in eyes with good visual acuity will improve or stabilize vision loss due to the complications of diabetic macular edema. The study is expected to be completed by December 2020.

Furthermore, increasing approval for new diabetic macular edema (DME) therapies is expected to propel growth for the macular edema treatment market. For instance, in March 2018, U.S. Food and Drug Administration (FDA) approved Lucentis (ranibizumab injection) 0.3 mg prefilled syringe (PFS) for diabetic macular edema and diabetic retinopathy. Lucentis 0.3 mg PFS is the first syringe prefilled with an anti-vascular endothelial growth factor (VEGF) agent. Moreover, in 2016 U.S.FDA approved Lucentis 0.5 mg PFS, which is intended for use in the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularisation (mCNV).

North America is expected to account for the largest market share in the macular edema treatment market, owing to increasing prevalence of diabetic macular edema in this region. For instance, according to American Journal of Managed Care (AJMC), in 2016, the prevalence rate of diabetic macular edema was 45.3% in North America.

Moreover, in 2013, as per National Center for Biotechnology Information (NCBI), around 98 million individuals reported for diabetic retinopathy (DR) and 21 million individual reported for diabetic macular edema (DME) worldwide.

Furthermore, increasing product approvals for the treatment of macular edema is expected to boost growth of the macular edema treatment market in Europe. For instance, in 2015, the European Commission approved Eylea (aflibercept) for the treatment of patients with macular edema secondary to retinal vein occlusion. Bayer HealthCare and Regeneron collaborated to develop Eylea. Bayer HealthCare has exclusive marketing rights to the product outside the U.S.

Click To Continue Reading On Macular Edema Treatment Market

Key players operating in the macular edema treatment market include, Novartis International AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc., Pfizer Inc. Bayer AG, Aerpio Therapeutics, Inc., Biomar Microbial Technologies, Antisense Therapeutics Limited, Coherus BioSciences, and Bausch & Lomb Incorporated.

Anti-infective Drugs Market Size, Emerging Evolution and Forecast 2018-2026

Key players in the market are focused on new product launch, which is expected to boost the Anti-Infective Drugs Market growth. For instance, in January 2018, Melinta Therapeutics, Inc. launched its intravenous and oral formulations of Baxdela (delafloxacin) in the U.S. Baxdela is intended for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria including gram positive bacteria and gram negative bacteria.

Get PDF Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2489

Moreover, increasing prevalence of sepsis is expected to boost growth of the anti-infective drug market. Sepsis is a life-threatening condition caused by the body’s response to an infection. For instance, according to the World Health Organization’s (WHO) report, 2018, over 30 million people worldwide are affected with sepsis that leads to 6 million deaths, annually. Moreover, over three million newborns and 1.2 million children suffer from sepsis worldwide, annually.

Furthermore, increasing number of pipeline studies to develop anti-infective drugs for the treatment of rare infectious diseases is contributing to growth of the anti-infective drugs market. For instance, in January 2019, National Institute of Allergy and Infectious Diseases (NIAID) initiated phase 2/phase 3 clinical trial to study the safety and effectiveness of four drugs including ZMapp, Remdesivir, MAb114, REGN-EB3, in people with Ebola virus infection. The study is expected to be complete by November 2024.

However, hypersensitivity reactions associated with administration of anti-infective drugs is expected to hamper growth of the anti-infective drugs market. For instance, in 2013, Clinical Infectious Diseases reported that in the study of self-reported antibiotic allergy prevalence, there was 9.0% of patients among 411 543 outpatients had a penicillin allergy documented in their medical record in San Diego County, California.

Growth and multiplication of harmful pathogens such as bacteria, viruses, fungi, and parasites causes major infections in the host body. Infection can be transmitted through skin contact, bodily fluids, airborne particles, or touching an infected object. Anti-infective drugs are used for the treatment of infectious diseases or conditions. Anti-infective drugs act by inhibiting the growth or by eliminating the infectious agents. For instance, in September 2018, Xellia Pharmaceuticals, a specialty pharmaceutical company that offers anti-infective drugs against serious and often life-threatening infections, started its new office in Buffalo Grove, near Chicago, Illinois to expand its sales and manufacturing capabilities within the U.S.

For instance, in September 2018, Astellas Pharma Inc. launched Dafclir Tablets 200 mg (fidaxomicin) for the treatment of infectious enteritis (including pseudomembranous colitis) in Japan. Astelles has also made an agreement with Merck in 2018 for development and marketing of Dafclir in Japan.

Click To Continue Reading On Anti-infective Drugs Market

Key players operating in the anti-infective drugs market include, Abbott Laboratories, Alcon Pharmaceuticals Ltd., Astellas Pharma Inc., AstraZeneca Plc., Bayer HealthCare AG, Alkem Labs, Pacific India Pharma Limited, Pfizer, and others.

Bio-engineered Stent Market Analysis and In-depth Research Growth and Forecast 2018-2026

Increasing prevalence of renal diseases is a major factor driving bio-engineered stents market growth. According to American Heart Association Council, in 2015, cardiovascular disease was the leading cause of death worldwide, accounting for over 17.9 million deaths annually and this number is expected to increase to over 23.6 million by 2030. According to the same source, cardiovascular diseases accounted for around 836,546 deaths in the U.S. in 2015, which accounted for around 1 in every 3 deaths.

Get a PDF Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2484

Moreover, key players in the market are focused on adopting various strategies such as new Product Type launch and approvals and partnerships and collaborations to increase their foothold in the market. For instance, in May 2017, Medtronic plc., received the U.S. Food and Drug Administration (FDA) approval and Resolute Onyx, 4.5 MM and 5 mm sizes Drug-Eluting Stent. This device has proven clinical performance and superior deliverability of the Resolute Integrity. This device is intended to treat people with coronary artery disease in the U.S.

However, availability of alternatives for the treatment of cardiac diseases, Product Type recalls and failure, and stringent regulations for Product Type approvals are expected to hinder the market growth. For instance in November 2017, Abbott recall Class 1 Device Recall Absorb Bioresorbable Vascular Scaffold (BVS) System, an absorbable coronary drug-eluting stent due to elevated rates of major adverse events, specifically, myocardial infraction and scaffold thrombosis when compared to patients treated with the Xience metallic drug eluting stent.

Key players in the market are focused on launching novel bio-engineered stent in order to reduce thrombus accumulation and address the critical unmet needs of patients in venous access. For instance, in May 2018, Abbott received the U.S. Food and Drug Administration (FDA) approval for XIENCE Sierra, a gold-standard XIENCE everolimus-eluting coronary stent system.

Similarly, in May, 2018, Pursuit Vascular, Inc., received the U.S. FDA clearance for broader indication of its ClearGuard HD caps to include reduction in the incidence of central-line associated bloodstream infection (CLABSI) in hemodialysis patients. In May 2017, Medtronic, Plc. received the U.S. FDA approval for its Resolute Onyx, a 2.0mm size zotarolimus-eluting stent with unique continuous sinusoid technology.

For instance, in February 2016, Maquet Medical Systems, a Getinge Group Company, announced plans to enter into partnership with Biotronik, a Germany-based manufacturer of cardiovascular and endovascular medical devices, to distribute Biotronik’s peripheral vascular devices in the U.S.

According to World Population Prospects, the number of people aged 80 or over is projected to triple by 2050, from 137 million in 2017 to 425 million in 2050 in the U.S. This age bracket is expected to more than double worldwide, increasing from 962 million in 2017 to 2.1 billion in 2050.

Moreover, key players in the market are focused on receiving regulatory approvals for novel products to reduce the burden of blood stream infections associated with bio-engineered stents. For instance, in September 2018, Biotronik SE & Co. KG received the U.S. Food and Drug Administration (FDA) approval for PK Papyrus covered coronary stent system for the treatment of acute coronary artery.

Click To Continue Reading On Bio-engineered Stent Market

Major players operating in the global bio-engineered stent market include, Medtronic, plc., Boston Scientific Corporation, Abbott Laboratories, Biotronik SE & Co. KG, B. Braun Melsungen AG, Terumo Corporation, MicroPort Scientific Corporation, Stentys Sao, Meril Life Sciences Pvt. Ltd, Vascular Concepts, W. L. Gore and Associates, C. R. Bard, Endologix, Inc., Lombard Medical Technologies, Translumina GmbH, and JOTEC GmbH.

Cell and Gene Therapy Market Estimated To Witness a Phenomenal Growth and Forecast 2018-2026

According to the World Cancer Research Funds and the American Institute for Cancer Research, in 2018, there were around 18 million cases of cancer, of which around 9.5 million were in men and around 8.5 million in women, globally. Moreover, introduction of innovative products and rich pipeline of cell and gene therapy is expected to boost the market growth. For instance, around 150 gene therapies are currently in the development stage. Gene replacement accounts for around two third of gene therapy pipeline. However, around 49% of gene therapies are under preclinical and discovery stages. During 2012-18, around 351 gene therapy deals were signed. For instance Gilead’s Kite Pharma received exclusive rights to Sangamo Therapeutics’ zinc finger nuclease gene editing technology, for $3.2bn.

Get a Request Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2475

According to the World Health Organization (WHO), May 2017, around 17.9 million people died due to cardiovascular disease in 2016 globally, which accounts for 31% of all worldwide deaths. According to WHO, in 2012, cancer was the second leading cause of morbidity and mortality globally, with around 14 million new cases registered in 2012 and in 2015, cancer was responsible for 8.8 million deaths, worldwide. Moreover, WHO stated that the number of new cases is expected to rise by around 70% by 2030.

Furthermore, introduction of effective guidelines is expected to propel growth of the global cell and gene therapy market over the forecast period. For instance, the U.S. Food and Drug Administration (FDA) included around 28 guidelines documents from 1998 to 2018 regarding various cell and gene therapies. However, several development challenges such as safety and efficacy issues, lengthy procedures for conducting clinical studies, stringent regulatory framework, and high costs are expected to limit the adoption of cell and gene therapy, thereby hindering the market growth.

Moreover, in November 2011, New York Blood Center, Inc. received approval from FDA for Hemacord. It is indicated for unrelated donor hematopoietic progenitor cell transplantation procedures and in patients with disorders affecting the hematopoietic system that are inherited, acquired, or results from myeloablative treatment in children. In October 2017, Kite Pharma received approval from the U.S. FDA for Yescarta (axicabtagene ciloleucel), which is used for the treatment of adults with large B-cell lymphoma. It was the first chimeric antigen receptor (CAR) T-cell therapy to receive FDA approval for large B-cell lymphoma.

For More Information On This Report, Please Visit @ https://www.coherentmarketinsights.com/market-insight/cell-and-gene-therapy-market-2475

Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance, in June 2017, Johnson & Johnson acquired Actelion Ltd. Moreover, in October 2017, Gilead Sciences acquired Kite Pharma. Kite Pharma is involved in developing chimeric antigen receptor T-cell therapy, to recognize and attack malignant cells.

Major players operating in the global cell and gene therapy market include Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., and MEDIPOST.

Idiopathic Pulmonary Fibrosis Treatment Market Set to Encounter Paramount Growth and Forecast 2018-2026

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease distinguished by progressive and irreversible reduction in lung function characterized by thickening and damaging of the walls of the air sacs (called alveoli). Major factors causing damage to the lungs include, acid reflux from stomach, certain viruses such as Epstein Barr virus and herpes virus or environmental factors such as breathing in dust such as silica dust, asbestos fibers, hard metal dust, and coal dust. Treatments for idiopathic pulmonary fibrosis (IPF) include, oxygen therapy, pulmonary rehabilitation, symptom management, and lung transplant. Prescribed antifibrotic drugs include, Pirfenidone and Nintedanib.

Get a Request Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2466

The idiopathic pulmonary fibrosis treatment market size is expected to witness significant growth, owing to increasing geriatric population. According to National Institute of Health’s (NIH), 2015 report, the symptoms of IPF starts occurring at the age of 50 to 70 in the U.S. Moreover, increasing prevalence of idiopathic pulmonary fibrosis is also expected to boost the market growth. According to NIH 2015 estimates, the prevalence of idiopathic pulmonary fibrosis is 13-20 per 100,000 people worldwide.

Smoking is believed to be another cause of idiopathic pulmonary fibrosis. According to the Centers for Disease Control and Prevention (CDC), around 1 billion smokers were recorded worldwide in 2017. The global idiopathic pulmonary fibrosis treatment market revenue is expected to witness significant growth, owing to availability of antifibrotic drugs IPF such as Pirfenidone (Esbriet) and Nintedanib (Ofev). According to annual reports of F. Hoffmann-La Roche AG, worldwide sales of Esbriet in 2016 was US$ 753 million.

Lack of awareness and availability of proper treatment is expected to hinder the idiopathic pulmonary fibrosis market growth. According to National Center for Biotechnology Information (NCBI) 2017 report, 54% patients do not receive any antifibrotic treatment in Europe.

Moreover, misdiagnosis of IPF is also expected to hinder the idiopathic pulmonary fibrosis treatment market size. For instance, according to Multidisciplinary Respiratory Medicines (MRM), in 2012, around 50% of IPF cases were misdiagnosed for other lung diseases in the U.S. High cost associated with the treatment of idiopathic pulmonary fibrosis is also expected to hinder the market growth. For instance, as per the data published in American Journal of Managed Care (AJMC) in 2014, idiopathic pulmonary fibrosis treatment requires US$ 100,000 annually, in the U.S.

According to NIH, 2015, around 100,000 people suffer from IPF and 30,000 to 40,000 new patients are diagnosed with the disease, annually in the U.S. Moreover, increasing approval of new drugs is also expected to boost the idiopathic pulmonary fibrosis treatment market growth in the region. For instance, in 2015, Prometic Life Sciences Inc. received the first orphan drug approval for PBI- 4050 from the U.S. Food and Drug Administration (FDA). Similarly, in 2017, Plasminogen (Ryplazim) was approved as an orphan drug by the U.S. FDA.

For More Information On This Report, Please Visit @ https://www.coherentmarketinsights.com/ongoing-insight/idiopathic-pulmonary-fibrosis-treatment-market-2466

Major players operating in the global idiopathic pulmonary fibrosis treatment market include, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb Company, Cipla, F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV, MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., and Prometic Life Sciences Inc.

Sinus Dilation Devices Market to See Incredible Growth and Forecast 2018-2026

Sinusitis is an inflammation of sinus, which causes nose blockage and avoids mucus drainage. Sinus dilation devices are used in patients with nose drainage issues related to nasal sinusitis or sinuses to expand the sinus openings. Different types of Sinus Dilation Devices can be utilized for patients according to the need of the treatment, which includes balloon sinuplasty systems, rhinoscopes, sinus stents, and functional endoscopic sinus surgery (FESS), and instruments set for sinuses or sinusitis. During balloon sinus dilation procedure, doctor reshapes the patient’s sinus pathway with inflated balloons to open the blocked sinus or nasal pathway.

Get a Request Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2451

Factors driving the sinus dilation devices market are increasing prevalence of chronic sinusitis, growing preference for minimally invasive surgeries, and favorable reimbursement scenario of surgical treatments for hospital outpatient department. According to the Centers for Disease Control and Prevention (CDC), in 2016, around 26.7 million adults in the U.S. were diagnosed with chronic sinusitis.

According to National Center for Biotechnology Information (NCBI), over 600,000 ambulatory sinonasal cases are performed each year in the U.S. Centers for Medicare Services (CMS) reassigned the nasal/sinus endoscopy codes, for instance, sphenoid balloon dilation (31297) and maxillary FESS procedures (31267) were reassigned to higher paying Ambulatory Payment Classifications (APCs). This resulted in a significant payment increase of 52.6%, which increased reimbursed cost of both the endoscopic sinus surgeries from US$ 2,009 in 2015 to US$ 3,066 in 2016.

According to the Centers for Disease Control and Prevention (CDC), in 2016, around 26.7 million adults in the U.S. were diagnosed with chronic sinusitis. Chronic sinusitis affects 146 per 1000 people in the U.S., while in Canada the estimated prevalence of diagnosed chronic sinusitis is around 2% to 2.5% of the population. Sinusitis results in over 18-22 million physician visits per year in the U.S. The socioeconomic burden is valued at US$ 3.4-5 billion annually, for the treatment of this chronic sinusitis.

Furthermore, according to the study published in the U.S. National Library of Medicine, up to 64% of the patients suffering from acquired immune deficiency syndrome (AIDS) have possibility to develop chronic sinusitis in their course of life.

For More Information On This Report, Please Visit @ https://www.coherentmarketinsights.com/market-insight/sinus-dilation-devices-market-2451

A study conducted by American Journal of Rhinology & Allergy in 2014, suggested that the complication rate for balloon sinuoplasty (BSP) was 5.26% and it was 7.35% for conventional functional endoscopic sinus surgery (FESS). Major complications associated with the endoscopic surgeries are due to balloon sinuplasty

Key players operating in the global sinus dilation devices market include, Entellus Medical, Inc., Smith & Nephew Plc., Acclarent, Inc., B. Braun Melsungen AG, Medtronic Plc, Olympus Corporation, SinuSys Corporation, InnAccel Technologies, Intersect ENT, Inc.